Research Analysts Issue Forecasts for iBio Q1 Earnings

iBio, Inc. (NASDAQ:IBIO) – Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of iBio in a report issued on Thursday, September 17th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for iBio’s current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for iBio’s Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.30) EPS, Q1 2028 earnings at ($0.09) EPS, Q2 2028 earnings at ($0.12) EPS, Q3 2028 earnings at ($0.16) EPS, Q4 2028 earnings at ($0.25) EPS, FY2028 earnings at ($0.62) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at ($0.57) EPS.

IBIO has been the topic of a number of other research reports. B. Riley Financial initiated coverage on shares of iBio in a report on Friday, June 5th. They issued a “buy” rating and a $6.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of iBio in a research note on Wednesday, June 24th. Chardan Capital restated a “buy” rating and set a $5.00 price objective on shares of iBio in a research note on Thursday, July 2nd. Raymond James Financial initiated coverage on shares of iBio in a research report on Monday, June 8th. They issued an “outperform” rating and a $5.00 target price for the company. Finally, Wall Street Zen lowered iBio from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. Four investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $5.29.

iBio Trading Down 1.6%

Shares of IBIO stock opened at $1.26 on Monday. The company has a market capitalization of $81.03 million, a price-to-earnings ratio of -3.71 and a beta of 1.29. The firm has a 50-day moving average price of $1.37 and a 200 day moving average price of $1.70. iBio has a twelve month low of $0.77 and a twelve month high of $3.82.

iBio (NASDAQ:IBIO) last posted its earnings results on Friday, August 28th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03.

Hedge Funds Weigh In On iBio

Institutional investors have recently modified their holdings of the company. EcoR1 Capital LLC acquired a new stake in shares of iBio in the fourth quarter valued at approximately $4,300,000. Frazier Life Sciences Management L.P. acquired a new position in shares of iBio during the fourth quarter worth approximately $3,770,000. Affinity Asset Advisors LLC boosted its position in shares of iBio by 51.0% during the first quarter. Affinity Asset Advisors LLC now owns 3,107,200 shares of the company’s stock worth $5,904,000 after buying an additional 1,050,000 shares during the period. Squarepoint Ops LLC bought a new position in iBio in the 2nd quarter worth approximately $873,000. Finally, Monashee Investment Management LLC acquired a new stake in iBio in the 4th quarter valued at approximately $530,000. Institutional investors own 7.90% of the company’s stock.

About iBio

iBio, Inc is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify antibody candidates and optimize their properties for potential use in cancer, autoimmune, inflammatory and fibrotic diseases.

iBio’s technology platform is based in part on the antibody-discovery capabilities obtained through its acquisition of RubrYc Therapeutics. The platform is designed to support target selection, antibody generation and optimization, with an emphasis on identifying antibodies that bind specific disease-related epitopes.